Global Programme to Eliminate Lymphatic Filariasis ... - libdoc.who.int

More documents

Recommendations

Info

94Annual Report on Lymphatic Filariasis 2003COOK ISLANDSThe entire country is LF-endemic. The pre-MDA surveyin 1999 showed a CFA prevalence of 8.6%. In 1965,a survey in Pukapuka showed 3.8% prevalence of lymphoedema.An MDA started on Aitukaki island in 1968reduced microfilaraemia from 30% to 0.8%.The first round of MDA started in 2000 with a reportedcoverage of 62.4%. In the second round in 2001, thereported coverage was 64.1%; for the third round it was98%. In 2003, the fourth MDA covered 18 700 peoplewith a reported coverage of 69.8%. Two drug distributionstrategies were chosen: door-to-door and booth distribution.Technical support was provided by WHO and additionalsupport for DEC and ICT cards was provided by the JICA.Chapter 3 Programme implementationFigure 3.135 LF at-risk populationPopulation in millions0.020 Total pop.0.0180.018 M0.0160.0140.0120.0100.0080.0060.0040.0020.000At-risk pop.0.018 MFigure 3.136 Geographical coverage% of at-risk population covered10075100 100 100 100502502000 2001 2002 2003Figure 3.137 MDA reported coverageFigure 3.138 IUs with reported coverage >65%1009810010010090808060%7062.464.169.8%40602050200020012002200300 02000200120022003
95FEDERATED STATES OF MICRONESIASome parts of the country are LF-endemic. The pre-MDA survey in 2000 showed a CFA prevalence of 0.2%.A study of clinical manifestations in 1992 showed ahydrocele and lymphoedema prevalence of 3.4% and0.4%, respectively. The first MDA round with the co-administration of albendazole plus DEC started in 2003;three islands were targeted with a reported coverageof 49.7%. Technical support was provided by WHO andadditional support for DEC and ICT cards was providedby the JICA.Annual Report on Lymphatic Filariasis 2003Figure 3.139 LF at-risk populationFigure 3.140 Geographical coveragePopulation in millions0.140.110.080.050.02-0.01Total pop.0.11 MAt-risk pop.0.11 M% of at-risk population covered100755025049.72003Chapter 3 Programme implementationFigure 3.141 MDA reported coverageFigure 3.142 IUs with reported coverage >65%10010090808060%70%60405049.720402003002003
Page 1 and 2:
For further information about lymph
Page 3:
WHO/CDS/CPE/CEE/2005.52GlobalProgra
Page 7 and 8:
3Report of the Technical Advisory G
Page 9 and 10:
P R O G R A M M E H I G H L I G H T
Page 11:
I N T R O D U C T I O N7This Annual
Page 14 and 15:
10Annual Report on Lymphatic Filari
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
38Figure 3.2 Outcomes and planning
Page 44 and 45:
Page 46 and 47:
42Figure 3.14 Outcomes and planning
Page 48 and 49: 44Figure 3.20 Outcomes and planning
Page 56 and 57: 52Annual Report on Lymphatic Filari
Page 59 and 60: UNITED REPUBLIC OF TANZANIA55Endemi
Page 61 and 62: ZANZIBAR, UNITED REPUBLIC OF TANZAN
Page 63: 59AMERICAN PROGRAMME REVIEWGROUPAt
Page 86 and 87: 82Figure 3.100 Outcomes and plannin
Page 104 and 105: 100Annual Report on Lymphatic Filar
Page 118 and 119: 114Figure 3.196 Outcomes and planni
Page 127: C H A P T E R 6FURTHER DOCUMENTATIO
Page 135 and 136: ANNUAL REPORT FOR THE NATIONAL PROG
Page 137 and 138: 1332. PROGRAMME RESOURCES2.1 Please
Page 139 and 140: 1353.3 Interruption of transmission
Page 141 and 142: 1373.3.6a Report of MDA coverage by
Page 143 and 144: 1393.3.7 Surveys in sentinel sites
Page 145 and 146: 1413.3.10 Please attach a map of th
Page 147 and 148: 1434. SERIOUS ADVERSE EXPERIENCES (
Page 149 and 150:
A N N E X E SANNEX 3: LIST OF LF-EN
Page 151 and 152:
147RAPLOARPRGSAESEAROTAG-LFTDRUNDPU
Page 153 and 154:
149Drug administration and monitori
show all

Global Programme to Eliminate Lymphatic Filariasis ... - libdoc.who.int

Create successful ePaper yourself

Delete template?

Save as template?